NCT03704714 - Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

December 11, 2024

Study Completion Date

June 11, 2025

Conditions

Aggressive Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaCD20 PositiveDiffuse Large B-Cell Lymphoma UnclassifiableIntravascular Large B-Cell LymphomaPrimary Mediastinal (Thymic) Large B-Cell LymphomaT-Cell/Histiocyte-Rich Large B-Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Prednisone

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (4)

60045

Northwestern University- Lake Forest Hospital, Lake Forest

60555

Northwestern Medicine: Delnor, DuPage, Warrenville, Kishwaukee (West Region), Warrenville

60611

Northwestern University, Chicago

60612

Rush University Medical Center, Chicago